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Received August 1, 2014; accepted October 30, 2014AbstractAcute or chronic insults to the liver are usually followed by a tissue repairing process. Unfortunately, this action, in most cases, is not
effective enough to restore the normal hepatic structure and function. Instead, fibrogenesis and regenerative nodules formation ensue, which are
relatively nonfunctioning. The common final stage of the process is liver cirrhosis with increased intrahepatic resistance to portal venous blood
flow. Throughout the entire course, the extrahepatic circulatory dysfunction, including increased splanchnic blood flow, elevated portal venous
blood flow and pressure, decreased splanchnic and peripheral vascular resistance, tachycardia, and increased cardiac output, are noted and
denoted as portal hypertension with hyperdynamic circulatory dysfunction. When such a condition is established, patients may suffer from fatal
complications such as gastroesophageal variceal hemorrhage, hepatic encephalopathy, or hepatorenal syndrome. The cause of such a circulatory
dysfunction is not fully elucidated. Nevertheless, clarification of the pathophysiology definitely contributes to the control of portal hypertension-
related complications. Herein, the molecular mechanism of this intriguing disaster is reviewed and discussed.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Liver cirrhosis has been notorious for its fatal complica-
tions for hundreds of years. Although much effort had been
made, the treatment efficacy was still suboptimal before subtle
information began to be unveiled. In 1953, based on the
observation that patients with cirrhosis were characterized by
increased flow of blood to the periphery as “warm extremities,
cutaneous vascular spiders, wide pulse pressure, and capillary
pulsations in the nail beds”, Kowalski and Abelmann1 firstConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assnoticed that cirrhosis was associated with a hyperdynamic
circulatory condition. They also demonstrated an elevated
cardiac output and decreased peripheral vascular resistance in
these patients. Astonished by these findings, the investigators
developed animal models to explore the mechanism. Scientists
now agree that the most critical point is how and when the
circulatory dysfunction is triggered and how it is maintained
and aggravated. Although marvelous advances have been
made in the past few decades, many more questions have been
raised and need to be addressed.2. Pathophysiology of hyperdynamic circulatory
syndrome in cirrhosis
According to Ohm's law, the pressure in a vascular system
is proportional to the resistance and flow in that system. Inociation. All rights reserved.
Fig. 1. Pathophysiological features of liver cirrhosis with hyperdynamic circulatory dysfunction. CO ¼ cardiac output; HR ¼ heart rate; MAP ¼ mean arterial
pressure; SVR ¼ systemic vascular resistance. Note: From “Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rat.,” by
S.J. Hsu, F.Y. Lee, S.S. Wang, I.F. Hsin, T.Y. Lin, H.C. Huang, et al, 2014, Hepatology, http://dx.doi.org/10.1002/hep.27679. Copyright © 2015 by the American
Association for the Study of Liver Diseases. Adapted with permission.
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blood flow are believed to play key roles in elevated portal
pressure (PP) (Fig. 1). Increased hepatic resistance is consid-
ered the primary event that triggers portal hypertension and
splanchnic/peripheral vasodilatation in cirrhosis. To cope with
the difficulty of sending portal tributary blood into the liver,
the shunt between portal and systemic vascular beds, the so
called portal-systemic collaterals, are established. Neverthe-
less, these are overwhelmed by the splanchnic vasodilation
and markedly increased splanchnic/portal blood flow. There-
after, PP elevates gradually. However, to compensate for the
decreased splanchnic and systemic vascular resistance that
lead to systemic hypotension, heart performance is compen-
satorily enhanced to elevate heart rate and cardiac output.
However, these actions are usually insufficient to reverse the
low blood pressure under the setting of marked peripheral
vasodilatation. Such a condition leads to decreased effective
intravascular volume, which stimulates vascular baroreceptors
and volume receptors. Then, sympathetic nervous system,
renin-angiotensin-aldosterone axis, and antidiuretic hormone
are activated, followed by sodium/water retention and volume
expansion. These are linked to complications such as edema,
ascites, and hepatorenal syndrome.
3. Molecular mechanism
Although not fully elucidated, it is generally accepted that
hyperdynamic circulatory dysfunction can be elicited by
increased vasodilatory substance release, dysregulated
response to vasoconstrictors, changes of vascular contractile
signaling, vascular remodeling, and angiogenesis (Fig. 2).3.1. Increased splanchnic vasodilatory substances
releaseIn contrast to impaired vasodilatory response in hepatic
microcirculation, in the splanchnic circulation, increased
vasodilatory substance production contributes to enhanced
endothelium-dependent relaxation, which precedes the devel-
opment of hyperdynamic circulatory syndrome in cirrhotic
portal hypertension.
3.1.1. Nitric oxide
Nitric oxide (NO) currently is the most recognized factor
related to extrahepatic vasodilatation in cirrhosis.2 It has been
found that patients with cirrhosis have increased serum levels
of NO metabolites.3 More specifically, the concentration of
NO metabolites in the portal venous plasma of patients with
cirrhosis is significantly higher than that in systemic venous
samples,4 suggesting that NO release is enhanced in
splanchnic vessels. A previous study also indicated that in
patients with cirrhosis, infusion of an NO synthase (NOS)
inhibitor increased forearm blood flow, supporting the role of
NO in peripheral vasodilation.5
NO is an endothelium-derived vasodilator synthesized
mainly by inducible (i)NOS and endothelial (e)NOS isoforms.
Endothelial NOS is upregulated by vascular shear stress and
acts via cofactors such as tetrahydrobiopterin (BH4).
6 Which is
the isoform that participates more in hyperdynamic circula-
tion? Although Vallance and Moncada7 proposed that iNOS
led to NO overproduction and subsequent hyperdynamic cir-
culation, substantial works have shown a lack of iNOS
expression in vessels from portal hypertensive animals despite
Fig. 2. Factors related to increased splanchnic blood flow and hyperdynamic circulatory syndrome. ADMA ¼ asymmetric dimethylarginine; BH4 ¼ tetrahy-
drobiopterin; CB1 ¼ cannabinoid receptor 1; CO ¼ carbon monoxide; DAH ¼ dimethylarginine dimethylaminohydrolase; eNOS ¼ endothelial nitric oxide
synthase; ET-1 ¼ endothelin-1; GTP-cyclohydrolase I ¼ guanosine triphosphateecyclohydrolase I; Hsp90 ¼ heat-shock protein 90; NO ¼ nitric oxide; NPY ¼
neuropeptide Y; PGI2 ¼ prostaglandin I2; PLGF ¼ placental growth factor; TNF-a¼ tumor necrosis factor-a; TRPV1 ¼ transient receptor potential cation channel
subfamily V member 1; VEGF ¼ vascular endothelial growth factor.
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than iNOS is the major contributor for NO overproduction and
hemodynamic derangements in portal hypertension.9 Indeed,
the superior mesenteric vascular bed from portal hypertensive
rats shows an enhanced NO production in response to shear
stress.10 On the molecular level, Tsai et al11 demonstrated that
eNOS activation occurs as early as 10 hours after the induction
of portal hypertension. Theodorakis et al,12 using iNOS- or
eNOS-knockout mice, also identified that eNOS participates
actively in the development of portal hypertension. Never-
theless, another study reported that eNOS knockout mice still
developed hyperdynamic circulation after partial portal vein
ligation (PVL), a surgical procedure to induce portal hyper-
tension. Therefore, NO seems to be the principal but not the
only mediator of portal hypertension, and compensatory
upregulation of vasodilators facing NO deficiency might be
implicated.13
Taking the upstream events into consideration, how is
eNOS-derived NO overproduction triggered? It has been
found that in rats with cirrhosis, bacterial translocation and
increased circulating endotoxin activate guanosine triphos-
phate (GTP)ecyclohydrolase I, which generates BH4 in
mesenteric arteries. This is followed by enhanced eNOS ac-
tivity and eNOS-derived NO overproduction.14,15 Further-
more, eNOS is regulated by various proteineprotein
interactions and posttranslational modification.6 For instance,
Akt/protein kinase B activates eNOS in the splanchnic arterialbed in portal hypertensive rats.16 Another finding is that PVL
induced a sudden increase of PP. This is followed by a
myogenic reflex and splanchnic vasoconstriction, which elicits
phosphorylation and upregulation of eNOS through Akt/pro-
tein kinase B activation, leading to increased NO production
and vasodilation.11,16 Consistently, Abraldes et al17 demon-
strated that a mild increase in PP upregulated intestinal
vascular endothelial growth factor (VEGF) and eNOS ex-
pressions, suggesting that PP itself triggers the cascade of
vasodilatory substances synthesis. An increased interaction of
eNOS with the molecular chaperone Hsp9019 also contributes
to the activation of eNOS at the posttranslational level. In
addition, a survey revealed the increased mesenterial arterial
messenger RNA expression of dimethylarginine dimethylami
nohydrolase-1 and -2, enzymes that degrade asymmetric
dimethylarginine, a NOS inhibitor, in portal hypertensive and
rats with cirrhosis.18
3.1.2. Tumor necrosis factor-a
Tumor necrosis factor alpha (TNF-a), released by mono-
nuclear cells in response to bacterial endotoxins, is a well-
known mediator of NO release.19 TNF-a inhibition blunts
the development of hyperdynamic circulation in rats with
portal hypertension20 and cirrhosis.21 Although it has been
proved that endotoxemia and TNF-a enhance NO release, why
does iNOS, the isoenzyme that is activated by inflammatory
mediators, play a less significant role than eNOS in portal
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NO synthesis, should be taken into consideration. In endo-
thelial cells, TNF-a and lipopolysaccharides upregulate the
key enzyme for BH4 biosynthesis, GTP-cyclohydrolase I.
22,23
Tetrahydrobiopterin then directly enhances eNOS-derived NO
bioavailability.24 It has been demonstrated that TNF-a and
lipopolysaccharide directly increased vascular NO synthesis in
the absence of iNOS induction by increasing the BH4 pro-
duction.22,25 In fact, BH4 increased in mesenteric vasculature
of rats with cirrhosis only under conditions of bacterial
translocation.15
3.1.3. Prostacyclin (prostaglandin I2, PGI2)
Prostacyclin is an endothelium-derived vasodilator synthe-
sized by cyclooxygenases. An increase in circulating PGI2 has
been observed in patients with cirrhosis.26 Furthermore, PGI2
participates in hyperdynamic circulation and PP elevation in
portal hypertensive rats.27 Indeed, the potential interaction
between prostacyclin and NO should be addressed; in portal
hypertensive rats with long-term prostacyclin inhibition, an
enhanced release of NO was noted. Such a finding suggested
that both vasodilatory systems interact to promote splanchnic
hyperemia in portal hypertension.28
3.1.4. Carbon monoxide
Carbon monoxide (CO) is an endogenous molecule with
vasodilatory properties.29 CO binds hemoglobin to generate
carboxyhemoglobin, an indicator of CO production. It has
been observed that concentrations of blood carbox-
yhemoglobin are significantly increased in patients with
cirrhosis.30 CO is produced from the breakdown of heme to
biliverdin via heme oxygenase (HO). Two isoforms of HO
have been identified: HO-1 and HO-2. Increased HO-1
expression was found in aortas and mesenteric arteries of
rats with cirrhosis. Zinc protoporphyrin, a selective HO in-
hibitor, ameliorates the hyperdynamic circulatory syndrome in
rats with cirrhosis, suggesting the role of CO in arterial
vasodilation.31
3.1.5. Angiotensin-(1e7)
A recent study has shown that systemic levels of the vas-
odilatory peptide angiotensin-(1-7) increase as liver fibrosis
progresses.32 In patients with cirrhosis at liver transplantation,
the angiotensin-(1-7)/angiotensin II ratio is elevated in the
splanchnic compared with the peripheral circulation, and
splanchnic but not systemic angiotensin peptide levels nega-
tively correlate with systemic vascular resistance.32 Angio-
tensin II is cleaved by angiotensin-converting enzyme-2 to
angiotensin-(1-7), which activates the G protein-coupled Mas
receptor (MasR) and gives rise to vasodilation. The effects of
angiotensin-(1-7)/MasR can be mediated by Gs protein and
protein kinase A33 or Akt-dependent pathways,34 which
stimulate eNOS phosphorylation and NO production.35,36
3.1.6. Adrenomedullin
Adrenomedullin is a potent vasodilatory peptide of which
the circulating level is increased in patients with cirrhosis.37Adrenomedullin is implicated in increased NO release and
plasma volume expansion, and its level is inversely correlated
with peripheral resistance.38 The implicated mechanisms
include phosphorylation and activation of Akt and the increase
of cGMP production.39 Antiadrenomedullin antibody admin-
istration ameliorated the blunted contractile response to
phenylephrine in aortas of rats with cirrhosis.40
3.1.7. Endocannabinoids
Endocannabinoids are a novel class of endogenous lipid
ligands; anandamide is an example.41 Endocannabinoids,
through their binding to the CB1 receptor, cause hypotension.
Anandamide is increased in monocytes in cirrhosis, and CB1
overactivation in mesenteric vasculature may contribute to
splanchnic vasodilation and portal hypertension.42 It has been
hypothesized that in cirrhosis with bacterial translocation and
endotoxemia, macrophages and monocytes release large
amounts of endocannabinoids.43 This leads to vasodilation via
activating the CB1 receptors located in the vessels and peri-
vascular nerves.42 Domenicali et al44 found that in rats with
cirrhosis, anandamide dose-dependently relaxed mesenteric
resistance arteries but not femoral arteries, providing evidence
of a selective endocannabinoid action in the splanchnic cir-
culation. Activation of endothelial CB1 receptors increased
NO production.42 However, one study revealed that the hy-
potensive effect of anandamide was not influenced by NOS
inhibitor or endothelial denudation, suggesting that NO does
not play a major role in this response.44 It is possible that CB1
is not the only receptor implicated in endocannabinoid-
mediated vasorelaxation. Indeed, anandamide can interact
with the transient receptor potential cation channel subfamily
V member 1 (TRPV1) receptor, which is expressed in peri-
vascular nerves, as demonstrated by the finding that the
concomitant use of CB1 inhibitor and capsazepine, a TRPV1
blocker, almost fully abolished anandamide-induced vasodi-
latation, demonstrating that both CB1 and TRPV1 receptors
mediate the endocannabinoid-induced vascular effect in
cirrhosis.45 Furthermore, a previous study has shown that
endocannabinoid-induced vasorelaxation also involved the
activation of vascular Kþ channels in cirrhotic mesenteric
arteries.463.2. Dysregulated response to vasoconstrictorsIt is well known that NO overproduction participates in
decreased vascular reactiveness to vasoconstrictors.14,47 In
addition to NO, recent evidence has indicated the roles of
various vasoactive substances in such an abnormal vascular
response.48e69
3.2.1. Endothelin-1
Endothelin-1 (ET-1), although known as a potent vaso-
constrictor, also exerts various effects via different receptors:
endothelin A (ETAR) and B receptors (ETBR1, ETBR2).
48 ET-
1 binds to ETAR and ETB2 to induce vasoconstriction, while
its binding to ETB1 leads to vasodilation.
49 A study of animals
with bile duct ligation (BDL)-induced biliary cirrhosis
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BDL. ETBR expression increased in vascular smooth muscle
cells and the microcirculation of mesenteric tissue, which was
implicated in the attenuated vasoconstriction and enhanced
vasodilation in splanchnic vasculature.50 Furthermore, endo-
thelin receptors can be desensitized by the phosphorylated G-
protein-coupled receptor kinases (GRKs) and the binding of b-
arrestin 2.51 b-arrestin 2 and GRK2 desensitize ETRs thor-
oughly, ETAR phosphorylation by GRK2 promotes the re-
ceptor binding to b-arrestin 2, which blocks the activation of G
proteins and leads to rapid desensitization; in addition, inde-
pendent of phosphorylation, GRK2 interacts with Gaq directly,
which results in upcoupling of ETRs and their associated G
proteins, thus impairing the ET-1 signaling.52 A recent study
revealed consistent finding that GRK2 expression was
increased significantly in rats with cirrhosis, resulting in ETAR
desensitization and splanchnic vasodilatation.50
3.2.2. Sympathetic neurotransmitters
The sympathetic nervous system activates as a compensa-
tory response to splanchnic and systemic vasodilation in
cirrhosis and portal hypertension. Markedly increased
norepinephrine concentrations in portal venous as compared to
arterial and/or peripheral blood samples in humans53 and an-
imals with portal hypertension54 have been noted. However,
prolonged adrenergic stimulation leads to diminished respon-
siveness to subsequent exposure to catecholamines. This is the
so-called ‘‘desensitization’’. Consequently, sustained sympa-
thetic overactivation may lead to vascular desensitization,
thereby aggravating splanchnic vasodilation in cirrhosis.55,56
3.2.3. Neuropeptide Y
Neuropeptide Y (NPY) is costored and coreleased with
norepinephrine from sympathetic nerve terminals, inducing
potentiation of a1-adrenergic vasoconstriction via G-protein-
associated postsynaptic Y1 receptors.57 NPY also sensitizes
vascular smooth muscle response to norepinephrine.58 The
diminished capability of sympathetic nerves to release NPY in
portal hypertensive splanchnic arteries and the regression of
sympathetic innervation in the mesenteric arterial tree had
been reported.59 It is possible that the increased systemic
norepinephrine level in cirrhosis60 may enhance the a2-
adrenergic presynaptic inhibition of NPY release.61 Repeated
stimulation of sympathetic nerves also leads to a depletion of
NPY release.62 Another linkage to decreased splanchnic NPY
action is elevated dipeptidyl-peptidase IV (DPP-IV) activity in
cirrhosis.63 Dipeptidyl-peptidase IV proteolytically processes
NPY64 so that elevated DPP-IV activity may reduce NPY ac-
tivity. Additionally, in the rat mesenteric bed, endothelins (ET-
1, ET-3) inhibited NPY release.65
3.2.4. Angiotensin-II
The renin-angiotensin-aldosterone system (RAAS) is acti-
vated as a homeostatic response to counterbalance the vaso-
dilatation in portal hypertension.66 The vasoconstrictive effect
of angiotensin-II is mediated via the type 1 receptor (AT1R).
However, increased expression of receptor desensitizingproteins, GRK2 and b-arrestin 2, has been implicated in
vascular hyporeactivity to angiotensin-Ⅱ in patients and rats
with cirrhosis. The desensitization of AT1R by GRK2 and b-
arrestin 2 changed patterns of phosphorylated Ca2þ-sensitizing
proteins and decreased Ca2þ sensitivity.67 In addition, because
receptor desensitization by GRKs and b-arrestins can be the
result of strong receptor activation by their cognate li-
gands,68,69 it is speculated that the elevated plasma concen-
trations of angiotensin-II in cirrhosis trigger the increased
binding of b-arrestin-2 to AT1 receptors in hypocontractile
vessels.3.3. Defective vascular contractile signalingAlthough much evidence has addressed the roles of
endothelium-derived vasoactive substances in splanchnic
vasodilation, some studies found that endothelium denudation
failed to improve vascular hyporeactivity to vasoconstric-
tors.67,70 Other studies also found that despite an attenuated
vascular reactivity to vasoconstrictors, the corresponding re-
ceptors were not downregulated or the receptor numbers and
affinities were not altered.71,72 Therefore, it is inferred that
defects in vascular signal transduction may exist. Actually,
in vitro and in vivo studies have indicated that vascular
hyporeactivity can be attributed to changes downstream of the
G-protein coupled receptors.67,70
It has been shown that mesenteric arteries from portal hy-
pertensive rats had a reduced level of membrane-associated
RhoA, probably reflecting a diminished activity of RhoA/
Rho kinase pathway followed by increased activity of myosin
light chain phosphatase and vasodilatation.73 Another study
provided evidence of defective Rho-kinase-mediated tone in
mesenteric vessels of BDL rats.74 In addition, Lin et al75 re-
ported that the formation of inositol trisphosphate after argi-
nine vasopressin stimulation in rats with cirrhosis was
substantially lower than that in sham-operated rats. The
alteration of PKC also participates, at least partly, in the
decreased vascular reactivity seen in rats with cirrhosis,76 and
NO plays a role in it.773.4. Vascular remodelingMany diseases affecting the cardiovascular system are
accompanied by structural modifications of the vascular wall,
so-called vascular remodeling. This process, unfortunately,
usually does not reverse, but rather exacerbates the original
circulatory dysfunction.78 A previous study indicated that the
conductance vessels of rats with cirrhosis that underwent
vascular remodeling. The most remarkable features are a
decrease in the thickness and total area of the vascular wall
and a reduction in the wall thickness/lumen diameter ratio,
which is an estimation of the vascular contraction capability.
Such an impairment was likely secondary to a decrease in the
amount of vascular smooth muscle cells because a diminution
in the number of nuclei in the medial layer of the vessels was
noted.79 Regarding the molecular mechanism, a reduction in
ERK1/2 phosphorylation, matrix metalloproteinases
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metalloproteinase-2 abundance in cirrhotic vessels were
noted, suggesting downregulation of cell growth, impaired
ERK1/2 activation, and subsequent imbalance of extracellular
matrix turnover.78 These could be reversed by NO inhibi-
tion,80 highlighting the pivotal role of NO in cirrhotic
vascular remodeling. In another study, in mesenteric arteries
from rats with cirrhosis, vessel strain was markedly elevated,
indicating a reduction in vessel stiffness. The findings from
strain-stress curve and elastic modulus in dependency on
vessel stress also supported the involvement of structure-
dependent factors. In addition, the cross-sectional area was
significantly increased, indicating the hypertrophic outward
remodeling.81 These structural changes may maintain and
aggravate the splanchnic vasodilation and increased flow in
cirrhosis.3.5. AngiogenesisIt is now recognized that the increase of portal inflow in
portal hypertension is due not only to splanchnic vasodilation
but also to enlargement of the splanchnic vasculature driven
by angiogenesis.82 In the splanchnic arteriolar territory, the
newly formed vessels accommodate the increased blood flow
to splanchnic organs associated with chronic portal hyper-
tension. Unfortunately, the pathological angiogenesis further
aggravates the splanchnic hyperdynamic circulation via
increased blood flow and portal-systemic collaterals forma-
tion. The first in vivo evidence for an increased angiogenesis in
the mesenteric microvasculature of rats with cirrhosis was
shown by Geerts et al.83 It has also been proved that growth
factors are upregulated in portal hypertension, and contribute
to the development and/or maintenance of increased
splanchnic blood flow.84
3.5.1. Vascular endothelial growth factor
VEGF was purified and cloned in the 1980s based on its
activities as a mitogen for endothelial cells.85 Since then, it has
become clear that VEGF plays a crucial role in angiogenesis.
A previous study has indicated that the mesenteric VEGF and
eNOS expressions increased in rats with cirrhosis and portal
hypertension.83 Actually, eNOS is a downstream mediator of
VEGF.86 Accumulating evidence further supports the benefi-
cial effects of VEGF blockade in ameliorating splanchnic
hyperdynamic circulation.87 In the process of neo-
vascularization, VEGF participates more in the initial stages
via activating proliferation of endothelial cells and formation
of endothelial tubules, whereas maturation of the newly
formed vessels is mainly modulated by platelet-derived growth
factor (PDGF), thereby stabilizing the vascular architecture of
the new vessel.88 Fernandez et al84 have proved that combined
inhibition of VEGF and PDGF signaling substantially reduced
splanchnic neovascularization and pericyte coverage of neo-
vessels, reflected by reductions in PP and superior mesenteric
artery blood flow. Portosystemic collateralization was reduced
as well.84 The precise mechanism triggering VEGF-dependentangiogenesis in portal hypertension remains not fully eluci-
dated. Indeed, several factors relevant to the pathogenesis of
portal hypertension, including tissue hypoxia, cytokines, and
mechanical stress, have been shown to upregulate VEGF
expression,89 and treatment strategies targeting at these up-
stream factors may be worth investigating.
3.5.2. Placental growth factor
Placental growth factor (PLGF) is a member of the VEGF
family and a specific ligand for VEGF receptor 1. Unlike
VEGF, PLGF plays a negligible role in physiological angio-
genesis. Studies in transgenic mice revealed that the angio-
genic activity of PLGF is restricted to pathologic conditions,
without affecting healthy vessels.90 A survey revealed that
PLGF is upregulated in mesenteric tissues of mice with portal
hypertension.82 PLGF deficiency prevented portosystemic
collateral formation and markedly ameliorated splanchnic
hyperemia.82 Furthermore, the PLGF knockout mice under-
going PVL did not develop mesenteric angiogenesis, and the
mesenteric CD31 (an endothelial marker that is used as the
index of angiogenesis) expression was significantly lower
compared with that in wild-type PVL mice.82
3.5.3. Pigment epithelium-derived factor
The angiogenesis inducer VEGF and the endogenous
negative regulator pigment epithelium-derived factor (PED)
are unidirectionally upregulated and significantly correlated
with pathological angiogenesis.91 PEDF elevates as a
compensatory response to avoid excessive pathological
angiogenesis.92 In vivo gene transfer of PEDF by adenoviral
vectors (AdPEDF) in BDL rats during early stages of liver
disease suppressed mesenteric pathological angiogenesis and
lowered PP. Nevertheless, the antiangiogenic actions of
AdPEDF were only modest when the adenovirus was given
during the advanced stage.93
3.5.4. Vasohibin-1
An endogenous angioinhibitor, vasohibin-1 (VASH1), has
been identified in a microarray analysis assessing genes
upregulated by VEGF in endothelial cells.94 Overexpressing
VASH1 protein in vivo by gene therapy with an adenoviral
vector (AdVASH1) substantially suppressed mesenteric path-
ological neovascularization and the severity of portosystemic
collaterals in rats with cirrhosis. The inhibitory effect of
AdVASH1 on angiogenesis could in part be explained by
disruption of the VEGF-VASH1 negative-feedback loop with
local downregulation of the excessive VEGF expression.95
4. Perspectives
Based on the encouraging investigations on molecular
mechanisms of circulatory derangements in cirrhotic portal
hypertension, it is anticipated that targeted treatment strategies
may contribute to a significant advance for patients with
cirrhosis also suffering from portal hypertension-related
complications.
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